Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

10 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

U-M study suggests new therapeutic strategy for treating Duchene muscular dystrophy

Every heart beat and step in our daily lives is dependent on the integrity of muscles and the proteins that keep them strong and free of injury as they contract and relax.

27 Oct 2015

Heart disease becomes the major killer of women in Norway

More research is carried out on breast cancer than on women's heart attack. Even though heart attack kills more women.

26 Oct 2015

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015

CV risk assessment essential for CML TKI trial design

The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology.

22 Oct 2015

Glycan binding proteins modify parasite infection in cells of the heart muscle

Chagas disease is the main cause of infectious heart disease in Latin America. Researchers from the INGEBI and IBYME Institutes in Argentina explored the effect of glycan binding protein interactions between the human host and Typanosoma cruzi parasite. They found that a glycan binding protein expressed in humans modified the infection in cells of the heart muscle, showing the importance of galectins in the response to parasite infection.

12 Oct 2015

SCT, Thermo Fisher Scientific collaborate to advance development of cardiac disease models

Stem Cell Theranostics announced today that they have successfully completed a research collaboration with Thermo Fisher Scientific focused on advancing the development of cardiac disease models derived from induced pluripotent stem cells using Thermo Fisher Scientific's suite of work flow reagents and SCT's patient biobank and proprietary disease modeling methods.

7 Oct 2015

Children with congenital heart disease and ADHD can benefit from stimulant medications

A new study finds that children with congenital heart disease and ADHD can take stimulant medications without fear of significant cardiovascular side effects.

5 Oct 2015

Yale ResearchKit app can help assess heart problems in children and young adults

Imagine being able to contribute to research about heart problems affecting children and adults with an iPhone app. That idea is now a reality with today's launch of the Yale Cardiomyopathy Index, an iPhone-based clinical study to better understand quality of life for people ages two to 80 who have or may develop a cardiomyopathy -- an abnormality in the heart muscle.

1 Oct 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Sticky, protein-rich gel improves cardiac function after simulated heart attacks

A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and restore their metabolism after transplantation, improving cardiac function after simulated heart attacks, according to results of a new study.

25 Sep 2015

Study challenges new ESC Guidelines to identify high-risk HCM patients who need ICDs for prevention of sudden death

Hypertrophic cardiomyopathy (HCM), a genetic form of heart disease with thick heart walls, is the most common cause of sudden death in patients under 50. While only a minority of patients with HCM are at risk, the implantable cardioverter-defibrillator (ICD) can effectively prevent sudden death in those patients.

22 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Surgeons participate in record-setting day of organ transplantation at Baylor University Medical Center

One week ago, surgical teams took part in a record-setting day of organ transplantation at Baylor University Medical Center at Dallas. Surgeons on the medical staff performed nine organ transplants on seven patients in one calendar day.

11 Sep 2015

European cardiomyopathies registry shows higher than expected use of defibrillators, genetic testing

The most representative snapshot of real world practice in cardiomyopathies in Europe has shown a higher than expected use of defibrillators and genetic testing. The baseline results of the ESC's EORP Cardiomyopathy Registry Pilot are presented for the first time today at ESC Congress 2015.

2 Sep 2015

Defibrillator does not improve outcomes in patients with CRT pacemaker

Most patients with a cardiac resynchronisation therapy (CRT) pacemaker would not benefit from the addition of a defibrillator, according to results from the CeRtiTuDe cohort study presented for the first time today at ESC Congress1 and published in European Heart Journal.

1 Sep 2015

BCM injection does not prevent cardiac remodeling in heart attack patients

An investigational material known Bioabsorbable Cardiac Matrix (BCM) that is injected through the coronary artery to prevent cardiac remodelling in heart attack patients had no significant effect compared to a saline placebo, according to results of the PRESERVATION I trial.

1 Sep 2015

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year period among patients with established Chagas disease (CD) cardiomyopathy, results of the BENEFIT trial show.

1 Sep 2015

Cardiomyopathy News and Research

Further Reading

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

New funding for Centenary's life saving research

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

U-M study suggests new therapeutic strategy for treating Duchene muscular dystrophy

Heart disease becomes the major killer of women in Norway

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

CV risk assessment essential for CML TKI trial design

Glycan binding proteins modify parasite infection in cells of the heart muscle

SCT, Thermo Fisher Scientific collaborate to advance development of cardiac disease models

Children with congenital heart disease and ADHD can benefit from stimulant medications

Yale ResearchKit app can help assess heart problems in children and young adults

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Sticky, protein-rich gel improves cardiac function after simulated heart attacks

Study challenges new ESC Guidelines to identify high-risk HCM patients who need ICDs for prevention of sudden death

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Surgeons participate in record-setting day of organ transplantation at Baylor University Medical Center

European cardiomyopathies registry shows higher than expected use of defibrillators, genetic testing

Defibrillator does not improve outcomes in patients with CRT pacemaker

BCM injection does not prevent cardiac remodeling in heart attack patients

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News